Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283208 | 0.93 | SMN1; SMN2 (0.49) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4279948 | 0.91 | KMT2A (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4292387 | 0.91 | HTT (0.54) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL5268713 | 0.89 | KMT2A (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4293270 | 0.88 | KDR (0.53) | ALDH1A1KMT2AKDM4EMAPTHTT | |
| SCHEMBL4279961 | 0.87 | KMT2A (0.51) | SMN1; SMN2ALDH1A1KMT2AKDM4EEPHX2 | |
| SCHEMBL4281447 | 0.86 | TSHR (0.51) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL5268958 | 0.86 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4286948 | 0.85 | KMT2A (0.50) | SMN1; SMN2ALDH1A1KMT2AMAPTEPHX2 | |
| SCHEMBL4279912 | 0.85 | KMT2A (0.51) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | RAB9A 291/4885NPC1 1266/4885SMN1; SMN2 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.